Dr. Karran believes that the clinical trials for the medicine have proven that the onset of Alzheimer’s could be slowed down with the use in the early stages of the disease.
Every year, more and more people are diagnosed with Alzheimer’s. it is a disease where the brain cells known as neurons die at an exponential rate resulting in dementia, loss of cognition and sense. For the human race, it is one of the worst diseases to date in which any person is reduced to a state of a vegetable with loss of memories and all basic brain functions.
Don't Miss: See the first leaked Black Friday 2016 Ad
Since its inception and perception of its severity, researchers and doctors have been trying to find a way to slow down the disease because curing it still seems like a long shot. In their efforts, the Alzheimer’s Research UK started clinical trial with the drug known as solanezumab.
The drug it seems, affected the production of amyloid protein around the synaptic bridge which caused the constriction of oxygen and wavelength and eventual death of the neurons. Researchers and specialists believe that amyloid deposition in the brain cells is the major cause of Alzheimer’s. The drug, it seems, reduces and stops the accumulation of amyloid in the brain cells.
The clinical trial ended as a failure in 2012 as a potential cure for the disease until the results of the study were re-analyzed by a US pharmaceutical company, Eli Lilly-the company responsible for developing the drug.
Close re-analysis revealed that although the drug did not cure Alzheimer’s, it made the onset of the disease slower by 30 percent. If given in the earlier days of the disease, it slowed down the rate of deterioration of the brain cells resulting in more time for the patients to remain lucid.
Dr Eric Karran, director of research at Alzheimer’s Research UK, explained that for the people who didn’t get the drug, the people on a placebo faced a deterioration in their disease, as was anticipated.
But in people who received the drug, the rate of their deterioration was slower by about 30%. So if you looked at the two groups at 1.5 years there was a clear difference between those who had been given the drug and those who didn’t get the drug. He added that this was the first time that we have seen a benefit that really looked like it was disease-modifying.
The announcement of the results of solanezumab and its findings will be revealed at the Alzheimer’s Association International conference in Washington, would be a landmark moment in the treatment of the disease.
Don't Miss: Sam's Club Black Friday 2016 Details